Key management and advisory personnel include a former executive of an electron microscope company, university genetics researchers, the director of a university genome center and successful entrepreneurs.
ZS Genetics management is focused on understanding evolving market needs, prioritizing technology development and maintaining intellectual property.
Before inventing the technology behind ZS Genetics, Mr. Glover worked as an energy industry economist, an energy industry management consultant, and a small business strategy consultant running the US Middle Market Strategy Practice for Cap Gemini Ernst & Young. Earlier, he worked for Bechtel Corporation, designing radiation safety systems for commercial nuclear power plants. Mr. Glover holds a Bachelor of Science degree in chemical engineering from California State University – Long Beach and a Master’s degree in Business Administration from the Darden School at the University of Virginia.
A serial entrepreneur with many successes to his credit, including ALIS, Micrion, Ion Beam Technologies and Varian, Bill is one of the premier scientists and business leaders in the charged particle microscopy community. He has authored numerous scientific articles for a number of professional journals and has lectured throughout the world. Numerous patents have been granted to Bill for his early breakthroughs in semiconductor-related technology – still considered some of the most important innovations in his field. Recently, his inventive skills and patents were focused on the stabilization of the Gas Field Ion Source, making possible a new generation of scanning charged particle microscopes, the Helium Ion Microscope.
ZS Genetic’s first investor, Mr. Abert offers a rich background in technology management, helping engineers move innovative technologies into commercial markets, and experience working with start-ups and finance. Highlights include helping launch and grow Hifi.com, a start-up venture for Cambridge SoundWorks, and helping PC Connection launch and manage their online business and service center. Early technology management experience was at AT&T, including Bell Labs, where he helped develop global multimedia networks and applications. His career began in finance, in both corporate finance and trading. Mr. Abert holds an AS in computer science and a BA in music theory from Keene State College and an MBA from the Darden School at the University of Virginia.
Larry, a seasoned physicist from the charged-particle microscope arena, is the VP of Technology for Platform Development. In this role he manages all of the research and development activities related to the electron microscope and takes an active role in the development of the imaging processes. Larry also holds an MBA and assists management in the areas of business planning. Prior to ZS Genetics, Larry worked on the science of creating the nanoscopic holes used in nanopore sequencing technology. His considerable experience with this form of sequencing has given us valuable insight to this technology and the predicted impediments with which nanopore competitors will be faced.
Suhaib is the VP of Technology for Chemistry, and is driving our labeling work and assisting management with business planning. He is in the top tier of nucleotide chemists in the world. Suhaib has extensive experience and success as both a Medicinal Chemist and a Computational Chemist. He has a background at NIH and several pharmaceutical companies, more than 30 publications in peer-review journals and 36 patents and patent applications. Suhaib is regularly invited to give lectures and seminars on biotechnology and drug development. Prior to ZSG, Suhaib was with Helicos Biosciences where his efforts led to their proprietary technology as an alternative to the Sanger Method for Sequencing, and which resulted in 27 patents and patents applications, as well as a publication in Nature.
ZSG management is also guided by an extensive network of advisers. These advisors have provided substantial improvement to the business model, market entry tactics and financial strategies.
Board of Directors
Before inventing the technology behind ZS Genetics, Mr. Glover worked as an energy industry economist, an energy industry management consultant, and a small business strategy consultant, running the US Middle Market Strategy Practice for Cap Gemini Ernst & Young. Earlier, he worked for Bechtel Corp., designing radiation safety systems for commercial nuclear power plants. Mr. Glover holds a BS in chemical engineering from CSU-Long Beach and an MBA from the Darden School at the University of Virginia.
ZS Genetic’s first investor, Mr. Abert offers a rich background in technology management, helping engineers move innovative technologies into commercial markets, and experience working with start-ups and finance. Highlights include helping launch and grow Hifi.com, a start-up venture for Cambridge SoundWorks, and helping PC Connection launch and manage their online business and service center. Early technology management experience was at AT&T, including Bell Labs, where he helped develop global multimedia networks and applications. His career began in finance, in both corporate finance and trading. Mr. Abert holds an AS in computer science and a BA in music theory from Keene State College, and an MBA from the Darden School at the University of Virginia.
Chairman of Curriculum Associates, Inc. (www.CAInc.com
). Mr. Ferguson is an active investor and member of the board or advisor for several companies in addition to ZS Genetics, including: Senscio Systems and NetClarity. He has been president of several corporations, including Bose Corporation for seven years, and Curriculum Associates, of which he is a founder.
Founder, CEO, President of Prescott Investment Corp., President of Pinnacle Mountain Partners; Managing Member, Angelfish Investments and Gulf Coast Investment Partners. Ms. Hager has extensive experience in the founding and management of public life sciences companies, including: IGI, Novavax, and National Medical Care. She also has extensive banking industry experience, including: founding director for Centrix Bank and Trust (where she is head of the Audit Committee), and director for Fleet Bank – New Hampshire.
An entrepreneur most of his career, Mr. Shields has owned and operated a number of businesses, ranging from the garment industry to steel fabrication. He currently is Chairman & CEO of Dalton Electric Heating Company, Chairman of the Massachusetts Group Insurance Commission, Chairman Emeritus of Massachusetts Family Institute, founding Chairman of Alpha New England, and founding Chairman of the Coalition for Marriage and Family. Previously Mr. Shields has been with Harvard Community Health Plan for 10 years, including as Chairman of the Finance Committee and President/CEO of Harvard Community Plan of New England. He has served on the Board of Advisors or Board of Directors for a number of privately held companies, ranging from internet startups to steel processing.
Scientific Advisory Board
Dr. Bell is the Gordon McKay Professor of the Practice of Electron Microscopy at the School of Engineering & Applied Sciences, and Manager of Imaging & Analysis at the Center for Nanoscale Systems, all at Harvard University. His current research interests include: nanocomposites and nanowire materials, investigating new mechanisms for materials imaging and analysis with charged particle beams, electron aberration determination, correction and the measurements and the application with analytical microscopy methods for advanced and adaptive correlative microscopy. He is widely published in journals and books and holds several patents. Dr. Bell did his postdoctoral studies at MIT, and received his Ph.D. from the University of Melbourne, Australia. He is a member of the Microscopy Society of America and Fellow of the Royal Microscopical Society, U.K.
Further information is available on Dr. Bell at www.bell.seas.harvard.edu.
Dr. Steven D. Berger has been Chief Executive Officer and President of Crystal IS, Inc. since September 2008. Dr. Berger served as Chief Operating Officer and Chief Technology Officer of FEI Company. During his time at FEI, he was part of the executive management team that grew FEI from $150MM to $600MM. His key focus brought new products to market profitably. Prior to FEI, he served as a Technical Manager to AT&T’s Bell Labs. He also taught at Cambridge University, UK. Dr. Berger holds 12 U.S. patents and is widely published in the fields of Electron Beam Lithography, Microscopy and Analysis. He serves as a Director of Crystal IS, Inc. Dr. Berger holds a PhD from the Cavendish University Laboratory at Cambridge University and BSc degree in Physics from the University of Salford.
Dr. Holick is a renowned endocrinologist and professor of medicine, biophysics and physiology at Boston University School of Medicine. He has extensively researched the sources and effects of Vitamin D on the body. In addition to his many academic and hospital appointments, Dr. Holick also has an extensive background with life sciences companies, including: A&D Bioscience, Strakan USA, IGI, Manhattan Pharmaceuticals, and Bridge to Life. He is the inventor of 42 approved or pending patents, holds numerous other awards, and has an extensive number of publications.
Further information is available on Dr. Holick at www.DrHolick.com.
Dr. Elaine Mardis graduated Phi Beta Kappa from the University of Oklahoma with a B.S. degree in zoology. She then completed her Ph.D. in Chemistry and Biochemistry in 1989, also at Oklahoma. Following graduation, Dr. Mardis was a senior research scientist for four years at BioRad Laboratories in Hercules, CA.
In 1993, Dr. Mardis joined The Genome Institute at Washington University School of Medicine. As Director of Technology Development, she helped create methods and automation pipelines for sequencing the Human Genome. She currently orchestrates the Center’s efforts to explore massively parallel sequencing technologies and to transition them into production sequencing capabilities as well as new applications.
Dr. Mardis has research interests in the application of DNA sequencing to characterize cancer genomes and transcriptomes, and using these data to support therapeutic decision-making. She also is interested in facilitating the translation of basic science discoveries about human disease into the clinical setting.
Dr. Mardis serves as an editorial board member of Molecular Cancer Research, Genome Research and Molecular Oncology, and acts as a reviewer for Nature, the New England Journal of Medicine, Cell and Genome Research. She serves on the scientific advisory boards of Qiagen Ingenuity, DNA Nexus, and ZS Genetics. Dr. Mardis received the Scripps Translational Research award for her work on cancer genomics in 2010, and was named a Distinguished Alumni of the University of Oklahoma College of Arts and Sciences for 2011. She is the former chair of Basic and Translational Sciences for the American College of Surgeons Oncology Group (ACOSOG).
Further information is available on Dr. Mardis at genome.wustl.edu/people/individual/elaine-mardis/.
Dr. Marziali received his B.A.Sc. in Engineering Physics from UBC in 1989, and his PhD in Physics from Stanford University in 1994. He subsequently worked for several years with Dr. Ron Davis, in the Stanford DNA Sequencing Technology Center, developing instruments for DNA sequencing and sample purification. He returned to Canada in 1998, as an assistant professor at University of British Columbia in the Department of Physics and Astronomy, where he formed the Applied Biophysics Laboratory. Shortly after his return to Canada, Dr. Marziali formed the GenomeBC Technology Development Platform, which he continues to lead as Co-Director. In 2005 he was appointed Director of the Engineering Physics program at UBC, a position he continues to hold in parallel with research and commercialization activities.
In 2004, Dr. Marziali co-invented the concept of using synchronous mobility perturbations to create divergent velocity fields for selectively focusing nucleic acids. This technology, termed SCODA, is the basis of a spin-off company, Boreal Genomics Inc. founded in 2007 by Dr. Marziali and colleagues to commercialize high performance instruments for DNA and RNA purification, and now developing novel cancer diagnostics methods. In the last few years he has been awarded the 2003 Killam Prize for Excellence in Teaching, the 2004 BC Innovation Council – Young Innovator award, the 2005 Canadian Association of Physicists Medal for excellence in teaching, the 2007 Association for Lab Automation Innovation Award, and the 2011 Life Science BC Award for Innovation and Achievement.
Boreal Genomics employs over 40 people in Vancouver, BC and a small commercial group in Los Altos CA, USA. It has recently been recognized by the National Research Council of Canada as a Canadian Innovation Leader, and by the Association for Lab Automation as one of its Top Ten breakthroughs of 2009.
Dr. Navin conducted his graduate training at the Cold Spring Harbor Laboratory and Stony Brook University, where he studied genome evolution in breast cancer. Dr. Navin conducted his postdoctoral training at the Cold Spring Harbor Laboratory under the mentorship of Dr. Michael Wigler, where he developed the first method for sequencing the genomes of individual human cells (Navin et al. 2011, Nature
). He applied this approach to study copy number evolution in triple-negative breast cancers, which revealed a punctuated model of chromosome evolution. These studies demonstrated the feasibility of sequencing the genomes of single cells and established the field of single cell genomics, which has lead to a myriad of applications in cancer research, immunology, development and microbiology.
Dr. Nicholas Navin is currently an assistant professor at the M.D. Anderson Cancer Center, where he holds a dual appointment in the Department of Genetics and the Department of Bioinformatics. The Navin laboratory uses both experimental methods and computational biology to study genomic diversity and mutational evolution in human tumors. The Navin laboratory is using single-cell sequencing techniques to study invasion, metastasis and resistance to chemotherapy in breast cancer and many other cancer types. The Navin lab is also actively pursuing the clinical applications of single-cell sequencing to improve diagnostics and therapeutic targeting of tumor cells in cancer patients.
Dr. Navin has been the recipient of a number of prestigious scholarships and fellowships, including the King & Miller scholarship, Abraham’s Award, Lindsay-Goldberg fellowship and the NCI T32 fellowship. Dr. Navin was recently awarded the Damon-Runyon Innovator Award from the Nadia’s Gift Foundation, the T.C Hsu Endowed Research Faculty Award and the Wilson S. Stone Award. Research from Dr. Navin has been highlighted in many news articles including Nature, Science, Nature Medicine, Scientific American, Nature Reviews Cancer, Nature Methods and the MIT Technology Review.
Robert Nicol is the director of the Broad Technology Labs, which serve as a center of multi-disciplinary innovation to support the Broad community, across molecular biology, microfluidics, microfabrication, advanced engineering, and industrial process design methods.
Nicol previously directed the Sequencing Operations and Technology Development for the Genome Sequencing Platform at the Broad. Before that, he was a project manager for Fluor Corporation, a $20B revenue Fortune 500 engineering and construction firm. He was responsible for the design, engineering, logistics, construction, and start-up of large- scale overseas projects for major petrochemical companies. In 1999, Nicol moved to MIT, where he was a fellow in the Leaders for Manufacturing Program, performing research on manufacturing systems and processes at Raytheon Missile Systems and Boeing.
Upon completing his fellowship at MIT in 2001, Nicol moved to the Whitehead Institute/MIT Center for Genome Research, now part of the Broad Institute, as the director of sequencing operations. In this role, he was responsible for implementing industrial process design, control, and improvement techniques to biological research. In his current role as Director of the Broad Technology Labs, Nicol leads a multi- disciplinary group focused on the convergence of biosciences, engineering, industrial methods, and physical sciences to catalyze the creation of new technologies to understand the molecular basis of biology and disease.
Nicol received a B.S. in mechanical engineering from the University of Houston and an M.B.A. and M.S. in chemical engineering from MIT. He earned his Ph.D. from the MIT Engineering Systems Division.
Mike was named Executive Vice President, Business Development and Chief Technology Officer at FEI company in July 2007. For 6 years prior to that, he worked as a consultant. His clients, located throughout North America and Europe, included major capital equipment manufacturers, venture capital and private equity firms, investment banks and small high-technology start-up companies. Before that he was director of U.S. research at FEI from 2000 to 2001. Previously, he held the tier-I NSERC Research Chair in Nanomagnetism/Physics at Simon Fraser University in Burnaby, BC and he was Professor of Physics at Arizona State University in Tempe, AZ. He also runs his own small software company, LLG Micromagnetics Simulator. Mike has a B.S. from Massachusetts Institute of Technology and a M.S. & Ph.D. from Cornell University.
Dr. Swerdlow is the Head of Sequencing Technology at the Wellcome Trust Sanger Institute (Sanger Centre). In this capacity, he is responsible for next-generation DNA sequencing instrumentation – technology assessment, acquisition and development. He also manages one of the largest DNA sequencing production facilities in the world, currently generating more than 500 billion bases of DNA sequence per week. Previously, he was the Chief Technology Officer at Dolomite Ltd., a DTI-funded microfabrication and microfluidics business, performing R&D project management and business development. Before Dolomite, he was the Senior Director of Research at Solexa Ltd. (now Illumina, Inc.), responsible for developing the technology that is now the most widely used for next- generation DNA sequencing. Before Solexa, he spent many years in academic research, managing various technology development projects. He has a long-standing interest in using miniaturization and microfluidic technology to solve problems in molecular biology and genome science.
Dr. Thomas is the Hubbard Professor in Genomics and Director of the Hubbard Center for Genome Studies, University of New Hampshire. Dr. Thomas and the HCGS staff have a focus on environmental genomics and the application of new technologies and the associated bioinformatics to study how organisms respond to environmental change. Dr. Thomas has a long academic career in genomics at the University of Missouri – Kansas City, and University of California – Berkeley, in addition to the University of New Hampshire. He has over 40 publications.